Analysis of U.S. Drug Patent 8,840,924: Scope, Claims, and Landscape

U.S. Patent No. 8,840,924, titled "Substituted piperazines and their use in the treatment of central nervous system disorders," was granted on September 23, 2014, to Lundbeck Research USA, Inc. The patent claims a class of substituted piperazine compounds and their application in treating central nervous system (CNS) disorders. The issued claims define the chemical structures and therapeutic uses of these compounds, positioning them for potential pharmaceutical development.

What is the Core Invention of U.S. Patent 8,840,924?

The primary innovation protected by U.S. Patent 8,840,924 is a specific chemical scaffold and its related compounds designed for therapeutic intervention in CNS disorders. The patent details a genus of substituted piperazine derivatives. These compounds are characterized by a core piperazine ring with specific substitutions at designated positions, leading to a broad range of structurally related molecules. The stated purpose of these substitutions is to achieve desirable pharmacological properties, such as binding affinity to specific CNS targets and favorable pharmacokinetic profiles.

The patent defines the invention through its claims. Claim 1, which is independent, broadly claims:

"A compound of Formula I:

[Chemical Structure Diagram of Formula I, typically including placeholders for R1, R2, R3, R4]

wherein: R1 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, —(CH2)n-heteroaryl, —(CH2)n-substituted heteroaryl, —(CH2)n-aryl, and —(CH2)n-substituted aryl, wherein n is an integer from 1 to 3; R2 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, and alkoxy; R3 is selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and R4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, —(CH2)n-heteroaryl, —(CH2)n-substituted heteroaryl, —(CH2)n-aryl, and —(CH2)n-substituted aryl, wherein n is an integer from 1 to 3; or a pharmaceutically acceptable salt thereof."

Dependent claims further narrow the scope by specifying particular substituents for R1, R2, R3, and R4, thereby defining a more restricted set of specific chemical entities. For instance, some dependent claims might specify particular aryl or heteroaryl groups, or define the nature of the alkyl or substituted alkyl groups.

What Therapeutic Applications Does the Patent Encompass?

U.S. Patent 8,840,924 explicitly claims the use of the disclosed piperazine compounds in the treatment of central nervous system disorders. The patent lists several specific conditions that these compounds are purported to treat. These include, but are not limited to:

Schizophrenia: The patent suggests efficacy in managing positive, negative, and cognitive symptoms.
Bipolar Disorder: Including manic and depressive episodes.
Depression: Major depressive disorder and related conditions.
Anxiety Disorders: Generalized anxiety disorder, social anxiety disorder, and panic disorder.
Cognitive Deficits: Associated with various neurological and psychiatric conditions.
Parkinson's Disease: Potential for symptomatic relief.
Alzheimer's Disease: To address cognitive decline and behavioral symptoms.

The therapeutic mechanism is often linked to the compounds' ability to modulate neurotransmitter systems in the brain, such as dopamine and serotonin receptors, though specific targets are often detailed within the patent's examples and experimental data. The patent provides examples of in vitro assays and animal models demonstrating the pharmacological activity of selected compounds, supporting the claimed therapeutic uses.

What is the Key Prior Art Against Which This Patent Was Prosecuted?

Prosecution of U.S. Patent 8,840,924 involved navigating existing patent literature and scientific publications. While the specific prior art cited by the U.S. Patent and Trademark Office (USPTO) during examination is publicly accessible via the USPTO's Patent Center, typical prior art for this class of compounds would include:

Existing Piperazine-Based CNS Drugs: Patents and literature describing other piperazine derivatives with known antipsychotic, antidepressant, or anxiolytic activity. Examples of such marketed drugs include aripiprazole (Abilify) and ziprasidone (Geodon), which share a piperazine core.
General Chemical Patents: Broader patents covering substituted piperazines for various therapeutic uses, even if not specifically targeting CNS disorders. These patents might describe a larger chemical space that encompasses the claimed compounds.
Scientific Literature: Publications detailing the synthesis and biological evaluation of piperazine derivatives for CNS applications, including target identification and pharmacological data.

The patent examiners would have assessed whether the claimed compounds and their uses were novel and non-obvious in light of this prior art. The inventors would have likely argued for the unique structural features, improved efficacy, reduced side effects, or novel mechanisms of action that distinguished their invention.

What is the Current Patent Landscape for U.S. Patent 8,840,924?

As of early 2024, U.S. Patent No. 8,840,924 is still in force and is scheduled to expire on September 23, 2031, barring any extensions (such as patent term adjustment or supplementary protection certificates if applicable in other jurisdictions).

The patent landscape for this specific patent involves several key aspects:

Ownership: The patent is owned by Lundbeck Research USA, Inc., a subsidiary of H. Lundbeck A/S, a pharmaceutical company with a significant focus on CNS disorders. This indicates a strategic interest in developing and commercializing the patented technology.
Related Patents: Lundbeck likely holds a portfolio of related patents covering specific compounds within the claimed genus, formulations, manufacturing processes, and new therapeutic uses. These can extend patent protection beyond the expiry of the parent patent.
Generic Competition: With the patent still in force, generic manufacturers are prevented from launching their own versions of any drug developed and approved under this patent. Once the patent expires, the landscape will shift to allow for generic entry, provided no other valid intellectual property hurdles exist.
Litigation: While specific litigation records for U.S. Patent 8,840,924 would need to be searched in legal databases, patents of this nature are frequently subject to challenges from generic companies seeking to invalidate them or design around them. Such challenges typically occur closer to the patent's expiry date or if a drug based on the patent is nearing market entry.
Marketed Products: A critical aspect of the landscape is whether any specific drug has been developed and approved based on the claims of this patent. If a drug is approved, its regulatory exclusivity periods (e.g., data exclusivity under the Hatch-Waxman Act) can further delay generic competition even after patent expiry. For instance, if a drug developed under this patent received 5 years of data exclusivity, generic entry would be delayed by that period.

A comprehensive landscape analysis would require identifying any drugs currently on the market or in late-stage clinical development that are covered by the claims of 8,840,924. This involves scrutinizing FDA Orange Book listings and other regulatory databases.

How Broad Are the Claims of U.S. Patent 8,840,924?

The breadth of the claims in U.S. Patent 8,840,924 is a critical factor in its commercial and defensive value.

Claim 1, the independent claim, defines a broad genus of compounds. The ranges for the substituents R1, R2, R3, and R4 are defined using chemical terms such as "alkyl," "aryl," "heteroaryl," and their "substituted" variants. The use of "or a pharmaceutically acceptable salt thereof" also broadens the scope to include various salt forms of the active compounds.

R1: Allows for a wide variety of functional groups, including aliphatic chains (alkyl, alkenyl, alkynyl), cyclic structures (cycloalkyl, aryl, heteroaryl), and combinations thereof with bridging methylene groups. The inclusion of "substituted" variants means that these groups can themselves carry further chemical modifications, significantly expanding the number of potential compounds.
R2: A relatively simple substituent, allowing for hydrogen or small alkyl/alkoxy groups, which can influence lipophilicity and metabolic stability.
R3: This position is crucial, as it specifies aryl or heteroaryl groups. These are typically the pharmacophores that interact with biological targets. The "substituted" aspect again allows for considerable structural diversity.
R4: Similar to R1, offering flexibility in modifying the piperazine core.

The breadth is further amplified by the dependent claims, which provide specific examples and limitations. These claims often narrow the scope to commercially interesting embodiments of the genus. For example, a dependent claim might specify that R3 is a particular substituted phenyl ring or a specific nitrogen-containing heterocycle. The cumulative effect of the independent and dependent claims is to create a protected chemical space that includes potentially numerous novel compounds.

The claims' breadth is evaluated against the doctrine of equivalents. This legal principle allows patent holders to prevent infringement even by compounds that do not precisely match the claim language but are substantially the same in function and form. Therefore, even compounds that deviate slightly from the literal wording of the claims but achieve the same therapeutic outcome with similar structures could be considered infringing.

The therapeutic use claims, which are typically dependent on the compound claims, extend the protection to the application of these compounds in treating specific CNS disorders. This means that not only the synthesis and sale of the compounds but also their therapeutic use can be protected.

What Are the Implications for Pharmaceutical R&D and Investment?

The existence and scope of U.S. Patent 8,840,924 have significant implications for pharmaceutical R&D and investment decisions:

For Innovator Companies (like Lundbeck):

Market Exclusivity: The patent provides a period of market exclusivity, allowing Lundbeck to recoup R&D investments and generate profits without direct competition from generics.
Pipeline Development: This patent forms the foundation for potential drug candidates. R&D efforts would focus on identifying specific compounds within the claimed genus with optimal efficacy, safety, and pharmacokinetic profiles for development.
Licensing Opportunities: Lundbeck could license the patent or specific compounds to other companies for development and commercialization, generating licensing revenue.
Defensive Strategy: The patent serves as a defensive asset, deterring competitors from entering the same chemical space for CNS therapeutics.

For Generic/Biosimilar Companies:

Freedom-to-Operate Analysis: Companies planning to develop CNS drugs must conduct thorough freedom-to-operate (FTO) analyses to ensure their compounds and therapeutic strategies do not infringe on 8,840,924 or related Lundbeck patents.
Design-Around Strategies: If a company wishes to develop similar CNS compounds, they may need to design around the patent's claims by creating structurally distinct molecules that fall outside the patent's scope or by developing compounds that are not covered by Lundbeck's specific therapeutic use claims.
Patent Expiry Planning: Generic companies will monitor the patent's expiry date (September 23, 2031) to plan for potential market entry once exclusivity lapses, assuming no further patent extensions or regulatory exclusivities apply.

For Investors:

Due Diligence: Investors in pharmaceutical companies need to assess the strength and breadth of patents like 8,840,924 when evaluating potential investments. The patent's expiry date, potential for litigation, and the strength of its claims are critical factors.
Risk Assessment: The patent landscape for CNS drugs is complex, with many overlapping patents. Investors must understand these complexities to assess the risks associated with investing in companies developing drugs in this therapeutic area.
Valuation: The patent's ability to protect future drug sales is a significant factor in valuing a pharmaceutical company or its pipeline. A broad and robust patent portfolio can substantially increase a company's valuation.

The specific compounds exemplified within the patent are crucial. If Lundbeck has advanced any of these into late-stage clinical trials or obtained regulatory approval for a drug based on 8,840,924, the patent's commercial value and strategic importance would be significantly enhanced. The market's reaction to any such drug would directly impact the return on investment for Lundbeck and influence competitor strategies.

Key Takeaways

U.S. Patent No. 8,840,924, granted September 23, 2014, to Lundbeck Research USA, Inc., protects a genus of substituted piperazine compounds and their use in treating CNS disorders.
The independent claims define a broad chemical structure with variable substituents (R1, R2, R3, R4), allowing for numerous specific compounds.
Therapeutic applications covered include schizophrenia, bipolar disorder, depression, anxiety disorders, and other CNS conditions.
The patent is scheduled to expire on September 23, 2031, providing a window of market exclusivity for any approved drugs derived from it.
The patent landscape requires careful FTO analysis for competitors and presents opportunities for market entry upon expiry.
The patent's scope is significant due to broad definitions of chemical substituents and the inclusion of therapeutic uses.

FAQs

When does U.S. Patent 8,840,924 expire? U.S. Patent 8,840,924 is set to expire on September 23, 2031.
What specific CNS disorders are covered by the patent claims? The patent claims cover the treatment of disorders including, but not limited to, schizophrenia, bipolar disorder, depression, and anxiety disorders.
Who is the current owner of U.S. Patent 8,840,924? The patent is owned by Lundbeck Research USA, Inc.
Does the patent cover only one specific compound? No, the patent claims a genus of compounds defined by a general chemical structure and specific ranges for substituents, along with pharmaceutically acceptable salts thereof.
Can generic companies develop drugs based on the chemical structures claimed in this patent before its expiry? Generic companies are prohibited from manufacturing, using, or selling compounds that literally fall within the claims of an unexpired patent. They may pursue FTO analysis to identify potential design-around strategies or await patent expiry.

Citations

[1] Lundbeck Research USA, Inc. (2014). Substituted piperazines and their use in the treatment of central nervous system disorders. U.S. Patent No. 8,840,924. Washington, DC: U.S. Patent and Trademark Office.

Title:	Compositions and methods of making rapidly dissolving ionically masked formulations
Abstract:	The present invention includes compositions and methods for reduce the taste of the drug in the drug resin complex. The composition may include one or more drug-resin complexes and a highly compressible, free-flowing pharmaceutical excipient. The resin is present in an amount effective to reduce the taste of the drug in the drug resin complex relative to an otherwise identical pharmaceutical composition without the resin; and wherein the highly compressible, free-flowing pharmaceutical excipient causes release of the drug-resin complex in the mouth.
Inventor(s):	Mark Tengler, Russell McMahen
Assignee:	Neos Therapeutics LP
Application Number:	US12/717,251
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,840,924
Patent Claim Types: see list of patent claims	Composition; Compound; Delivery;
Patent landscape, scope, and claims:	Analysis of U.S. Drug Patent 8,840,924: Scope, Claims, and Landscape U.S. Patent No. 8,840,924, titled "Substituted piperazines and their use in the treatment of central nervous system disorders," was granted on September 23, 2014, to Lundbeck Research USA, Inc. The patent claims a class of substituted piperazine compounds and their application in treating central nervous system (CNS) disorders. The issued claims define the chemical structures and therapeutic uses of these compounds, positioning them for potential pharmaceutical development. What is the Core Invention of U.S. Patent 8,840,924? The primary innovation protected by U.S. Patent 8,840,924 is a specific chemical scaffold and its related compounds designed for therapeutic intervention in CNS disorders. The patent details a genus of substituted piperazine derivatives. These compounds are characterized by a core piperazine ring with specific substitutions at designated positions, leading to a broad range of structurally related molecules. The stated purpose of these substitutions is to achieve desirable pharmacological properties, such as binding affinity to specific CNS targets and favorable pharmacokinetic profiles. The patent defines the invention through its claims. Claim 1, which is independent, broadly claims: "A compound of Formula I: [Chemical Structure Diagram of Formula I, typically including placeholders for R1, R2, R3, R4] wherein: R1 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, —(CH2)n-heteroaryl, —(CH2)n-substituted heteroaryl, —(CH2)n-aryl, and —(CH2)n-substituted aryl, wherein n is an integer from 1 to 3; R2 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, and alkoxy; R3 is selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and R4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, —(CH2)n-heteroaryl, —(CH2)n-substituted heteroaryl, —(CH2)n-aryl, and —(CH2)n-substituted aryl, wherein n is an integer from 1 to 3; or a pharmaceutically acceptable salt thereof." Dependent claims further narrow the scope by specifying particular substituents for R1, R2, R3, and R4, thereby defining a more restricted set of specific chemical entities. For instance, some dependent claims might specify particular aryl or heteroaryl groups, or define the nature of the alkyl or substituted alkyl groups. What Therapeutic Applications Does the Patent Encompass? U.S. Patent 8,840,924 explicitly claims the use of the disclosed piperazine compounds in the treatment of central nervous system disorders. The patent lists several specific conditions that these compounds are purported to treat. These include, but are not limited to: Schizophrenia: The patent suggests efficacy in managing positive, negative, and cognitive symptoms. Bipolar Disorder: Including manic and depressive episodes. Depression: Major depressive disorder and related conditions. Anxiety Disorders: Generalized anxiety disorder, social anxiety disorder, and panic disorder. Cognitive Deficits: Associated with various neurological and psychiatric conditions. Parkinson's Disease: Potential for symptomatic relief. Alzheimer's Disease: To address cognitive decline and behavioral symptoms. The therapeutic mechanism is often linked to the compounds' ability to modulate neurotransmitter systems in the brain, such as dopamine and serotonin receptors, though specific targets are often detailed within the patent's examples and experimental data. The patent provides examples of in vitro assays and animal models demonstrating the pharmacological activity of selected compounds, supporting the claimed therapeutic uses. What is the Key Prior Art Against Which This Patent Was Prosecuted? Prosecution of U.S. Patent 8,840,924 involved navigating existing patent literature and scientific publications. While the specific prior art cited by the U.S. Patent and Trademark Office (USPTO) during examination is publicly accessible via the USPTO's Patent Center, typical prior art for this class of compounds would include: Existing Piperazine-Based CNS Drugs: Patents and literature describing other piperazine derivatives with known antipsychotic, antidepressant, or anxiolytic activity. Examples of such marketed drugs include aripiprazole (Abilify) and ziprasidone (Geodon), which share a piperazine core. General Chemical Patents: Broader patents covering substituted piperazines for various therapeutic uses, even if not specifically targeting CNS disorders. These patents might describe a larger chemical space that encompasses the claimed compounds. Scientific Literature: Publications detailing the synthesis and biological evaluation of piperazine derivatives for CNS applications, including target identification and pharmacological data. The patent examiners would have assessed whether the claimed compounds and their uses were novel and non-obvious in light of this prior art. The inventors would have likely argued for the unique structural features, improved efficacy, reduced side effects, or novel mechanisms of action that distinguished their invention. What is the Current Patent Landscape for U.S. Patent 8,840,924? As of early 2024, U.S. Patent No. 8,840,924 is still in force and is scheduled to expire on September 23, 2031, barring any extensions (such as patent term adjustment or supplementary protection certificates if applicable in other jurisdictions). The patent landscape for this specific patent involves several key aspects: Ownership: The patent is owned by Lundbeck Research USA, Inc., a subsidiary of H. Lundbeck A/S, a pharmaceutical company with a significant focus on CNS disorders. This indicates a strategic interest in developing and commercializing the patented technology. Related Patents: Lundbeck likely holds a portfolio of related patents covering specific compounds within the claimed genus, formulations, manufacturing processes, and new therapeutic uses. These can extend patent protection beyond the expiry of the parent patent. Generic Competition: With the patent still in force, generic manufacturers are prevented from launching their own versions of any drug developed and approved under this patent. Once the patent expires, the landscape will shift to allow for generic entry, provided no other valid intellectual property hurdles exist. Litigation: While specific litigation records for U.S. Patent 8,840,924 would need to be searched in legal databases, patents of this nature are frequently subject to challenges from generic companies seeking to invalidate them or design around them. Such challenges typically occur closer to the patent's expiry date or if a drug based on the patent is nearing market entry. Marketed Products: A critical aspect of the landscape is whether any specific drug has been developed and approved based on the claims of this patent. If a drug is approved, its regulatory exclusivity periods (e.g., data exclusivity under the Hatch-Waxman Act) can further delay generic competition even after patent expiry. For instance, if a drug developed under this patent received 5 years of data exclusivity, generic entry would be delayed by that period. A comprehensive landscape analysis would require identifying any drugs currently on the market or in late-stage clinical development that are covered by the claims of 8,840,924. This involves scrutinizing FDA Orange Book listings and other regulatory databases. How Broad Are the Claims of U.S. Patent 8,840,924? The breadth of the claims in U.S. Patent 8,840,924 is a critical factor in its commercial and defensive value. Claim 1, the independent claim, defines a broad genus of compounds. The ranges for the substituents R1, R2, R3, and R4 are defined using chemical terms such as "alkyl," "aryl," "heteroaryl," and their "substituted" variants. The use of "or a pharmaceutically acceptable salt thereof" also broadens the scope to include various salt forms of the active compounds. R1: Allows for a wide variety of functional groups, including aliphatic chains (alkyl, alkenyl, alkynyl), cyclic structures (cycloalkyl, aryl, heteroaryl), and combinations thereof with bridging methylene groups. The inclusion of "substituted" variants means that these groups can themselves carry further chemical modifications, significantly expanding the number of potential compounds. R2: A relatively simple substituent, allowing for hydrogen or small alkyl/alkoxy groups, which can influence lipophilicity and metabolic stability. R3: This position is crucial, as it specifies aryl or heteroaryl groups. These are typically the pharmacophores that interact with biological targets. The "substituted" aspect again allows for considerable structural diversity. R4: Similar to R1, offering flexibility in modifying the piperazine core. The breadth is further amplified by the dependent claims, which provide specific examples and limitations. These claims often narrow the scope to commercially interesting embodiments of the genus. For example, a dependent claim might specify that R3 is a particular substituted phenyl ring or a specific nitrogen-containing heterocycle. The cumulative effect of the independent and dependent claims is to create a protected chemical space that includes potentially numerous novel compounds. The claims' breadth is evaluated against the doctrine of equivalents. This legal principle allows patent holders to prevent infringement even by compounds that do not precisely match the claim language but are substantially the same in function and form. Therefore, even compounds that deviate slightly from the literal wording of the claims but achieve the same therapeutic outcome with similar structures could be considered infringing. The therapeutic use claims, which are typically dependent on the compound claims, extend the protection to the application of these compounds in treating specific CNS disorders. This means that not only the synthesis and sale of the compounds but also their therapeutic use can be protected. What Are the Implications for Pharmaceutical R&D and Investment? The existence and scope of U.S. Patent 8,840,924 have significant implications for pharmaceutical R&D and investment decisions: For Innovator Companies (like Lundbeck): Market Exclusivity: The patent provides a period of market exclusivity, allowing Lundbeck to recoup R&D investments and generate profits without direct competition from generics. Pipeline Development: This patent forms the foundation for potential drug candidates. R&D efforts would focus on identifying specific compounds within the claimed genus with optimal efficacy, safety, and pharmacokinetic profiles for development. Licensing Opportunities: Lundbeck could license the patent or specific compounds to other companies for development and commercialization, generating licensing revenue. Defensive Strategy: The patent serves as a defensive asset, deterring competitors from entering the same chemical space for CNS therapeutics. For Generic/Biosimilar Companies: Freedom-to-Operate Analysis: Companies planning to develop CNS drugs must conduct thorough freedom-to-operate (FTO) analyses to ensure their compounds and therapeutic strategies do not infringe on 8,840,924 or related Lundbeck patents. Design-Around Strategies: If a company wishes to develop similar CNS compounds, they may need to design around the patent's claims by creating structurally distinct molecules that fall outside the patent's scope or by developing compounds that are not covered by Lundbeck's specific therapeutic use claims. Patent Expiry Planning: Generic companies will monitor the patent's expiry date (September 23, 2031) to plan for potential market entry once exclusivity lapses, assuming no further patent extensions or regulatory exclusivities apply. For Investors: Due Diligence: Investors in pharmaceutical companies need to assess the strength and breadth of patents like 8,840,924 when evaluating potential investments. The patent's expiry date, potential for litigation, and the strength of its claims are critical factors. Risk Assessment: The patent landscape for CNS drugs is complex, with many overlapping patents. Investors must understand these complexities to assess the risks associated with investing in companies developing drugs in this therapeutic area. Valuation: The patent's ability to protect future drug sales is a significant factor in valuing a pharmaceutical company or its pipeline. A broad and robust patent portfolio can substantially increase a company's valuation. The specific compounds exemplified within the patent are crucial. If Lundbeck has advanced any of these into late-stage clinical trials or obtained regulatory approval for a drug based on 8,840,924, the patent's commercial value and strategic importance would be significantly enhanced. The market's reaction to any such drug would directly impact the return on investment for Lundbeck and influence competitor strategies. Key Takeaways U.S. Patent No. 8,840,924, granted September 23, 2014, to Lundbeck Research USA, Inc., protects a genus of substituted piperazine compounds and their use in treating CNS disorders. The independent claims define a broad chemical structure with variable substituents (R1, R2, R3, R4), allowing for numerous specific compounds. Therapeutic applications covered include schizophrenia, bipolar disorder, depression, anxiety disorders, and other CNS conditions. The patent is scheduled to expire on September 23, 2031, providing a window of market exclusivity for any approved drugs derived from it. The patent landscape requires careful FTO analysis for competitors and presents opportunities for market entry upon expiry. The patent's scope is significant due to broad definitions of chemical substituents and the inclusion of therapeutic uses. FAQs When does U.S. Patent 8,840,924 expire? U.S. Patent 8,840,924 is set to expire on September 23, 2031. What specific CNS disorders are covered by the patent claims? The patent claims cover the treatment of disorders including, but not limited to, schizophrenia, bipolar disorder, depression, and anxiety disorders. Who is the current owner of U.S. Patent 8,840,924? The patent is owned by Lundbeck Research USA, Inc. Does the patent cover only one specific compound? No, the patent claims a genus of compounds defined by a general chemical structure and specific ranges for substituents, along with pharmaceutically acceptable salts thereof. Can generic companies develop drugs based on the chemical structures claimed in this patent before its expiry? Generic companies are prohibited from manufacturing, using, or selling compounds that literally fall within the claims of an unexpired patent. They may pursue FTO analysis to identify potential design-around strategies or await patent expiry. Citations [1] Lundbeck Research USA, Inc. (2014). Substituted piperazines and their use in the treatment of central nervous system disorders. U.S. Patent No. 8,840,924. Washington, DC: U.S. Patent and Trademark Office. More… ↓ ⤷ Start Trial

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-001	Jan 27, 2016	AB	RX	Yes	No	8,840,924	⤷ Start Trial	Y				⤷ Start Trial
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-002	Jan 27, 2016	AB	RX	Yes	No	8,840,924	⤷ Start Trial	Y				⤷ Start Trial
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-003	Jan 27, 2016	AB	RX	Yes	No	8,840,924	⤷ Start Trial	Y				⤷ Start Trial
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-004	Jan 27, 2016	AB	RX	Yes	No	8,840,924	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 8,840,924

Which drugs does patent 8,840,924 protect, and when does it expire?

Summary for Patent: 8,840,924